CoChat
Sign Up
Cited by 51Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedical Imaging Techniques and Applications

The effect of ApoE ε4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study

Open access
Paranjpe, Manish D., Chen, Xueqi, Liu, Min, Paranjpe, Ishan, Leal, Jeffrey P., Wang, Rongfu, Pomper, Martin G., Wong, Dean F. +2 more·2019·NeuroImage: Clinical
DOI 10.1016/j.nicl.2019.101795PMC PMC6449776
Open this paper in CoChat — free accountOpen PDF

Abstract

While the ApoE ε4 allele is a known risk factor for mild cognitive impairment (MCI) and Alzheimer's disease, brain region specific effects remain elusive. In this study, we investigate whether the ApoE ε4 allele exhibits brain region specific effects in longitudinal glucose uptake among patients with MCI from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Preprocessed FDG PET images, MRIs, and demographic information were downloaded from the ADNI database. An iterative reblurred Van Cittertiteration method was used for partial volume correction (PVC) on all PET images. Structural MRIs were used for PET spatial normalization and region of interest (ROI) definition in standard space. Longitudinal changes in ROI FDG standardized uptake value ratio (SUVR) relative to cerebellum in 24 ApoE ε4 carriers and 24 age-matched ApoE ε4 non-carriers were measured for up to 84-months (median 72 months, SD = 11.2 months) and compared using a generalized linear mixed effects model controlling for gender, education, baseline age, and follow-up period. Additionally, voxelwise analysis was performed by implementing a paired t-test comparing matched baseline and 72 month FDG SUVR images in ApoE carriers and non-carriers separately. Results with PVC were compared with ones from non-PVC based analysis. After applying PVC, the superior fontal, parietal, lateral temporal, medial temporal, caudate, thalamus, and post-cingulate, and amygdala regions had greater longitudinal decreases in FDG uptake in ApoE ε4 carriers with MCI compared to non-carriers with MCI. Similar forebrain and limbic clusters were found through voxelwise analysis. Compared to the PVC based analysis, fewer significant ApoE-associated regions and clusters were found in the non-PVC based PET analysis. Our findings suggest that the ApoE ε4 genotype is associated with a longitudinal decline in glucose uptake in 8 forebrain and limbic brain regions in the context of MCI. In conclusion, this 84-months longitudinal FDG PET study demonstrates a novel ApoE ε4-associated brain-region specific glucose metabolism pattern in patients with MCI. Partial volume correction improved FDG PET quantification.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nicl.2019.101795

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Regional metabolic deficits closely mirror mitochondrial bioenergetic decline, suggesting cerebral hypometabolism represents an in vivo biomarker of mitochondrial dysfunction rather than an isolated process.

    “These regional metabolic deficits closely mirror mitochondrial bioenergetic decline, suggesting that cerebral hypometabolism represents an in vivo biomarker of mitochondrial dysfunction rather than an isolated process [66, 68].”

    From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [68]

    The Conclusion (page unavailable) reports regional declines in FDG uptake in ApoE ε4 carriers with mild cognitive impairment, supporting the regional hypometabolism component. Neither it nor the retrieved Introduction and Discussion passages reports mitochondrial bioenergetic decline or establishes hypometabolism as a biomarker of mitochondrial dysfunction (searched: mitochondrial bioenergetic decline, mitochondrial dysfunction, oxidative phosphorylation). (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 65

  1. Beason-Held L.L. Goh J.O. An Y. Kraut M.A. O'Brien R.J. Ferrucci L. Resnick S.M. Changes in brain function occur years before the onset of cognitive impairment J. Neurosci. 2013 PMC3828456 24227712
  2. Bischof G.N. Jessen F. Fliessbach K. Dronse J. Hammes J. Neumaier B. Onur O. Fink G.R. Kukolja J. Drzezga A. van Eimeren T. Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease Ann. Clin. Transl. Neurol. 2016 PMC5224823 28097205
  3. Breslow J.L. Zannis V.I. SanGiacomo T.R. Third J.L. Tracy T. Glueck C.J. Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2 J. Lipid Res. 23 1982 1224 1235 7175379
  4. Bruscoli M. Lovestone S. Is MCI really just early dementia? A systematic review of conversion studies Int. Psychogeriatrics. 2004 15318760
  5. Chan D. Janssen J.C. Whitwell J.L. Watt H.C. Jenkins R. Frost C. Rossor M.N. Fox N.C. Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study Lancet 362 2003 1121 1122 14550701
  6. Chen X. Zhou Y. Wang R. Cao H. Reid S. Gao R. Han D. Potential clinical value of multiparametric pet in the prediction of Alzheimer's disease progression PLoS One 11 2016 PMC4868310 27183116
  7. Cohen A.D. Klunk W.E. Early detection of Alzheimer's disease using PiB and FDG PET Neurobiol. Dis. 2014 PMC4226742 24825318
  8. Cope T.E. Rittman T. Borchert R.J. Jones P.S. Vatansever D. Allinson K. Passamonti L. Vazquez Rodriguez P. Bevan-Jones W.R. O'Brien J.T. Rowe J.B. Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy Brain 141 2018 550 567 29293892 PMC5837359
  9. Dickens A.M. Yoo S.W. Chin A.C. Xu J. Johnson T.P. Trout A.L. Hauser K.F. Haughey N.J. Chronic low-level expression of HIV-1 tat promotes a neurodegenerative phenotype with aging Sci. Rep. 2017 PMC5552766 28798382
  10. Drzezga A. Riemenschneider M. Strassner B. Grimmer T. Peller M. Knoll A. Wagenpfeil S. Minoshima S. Schwaiger M. Kurz A. Cerebral glucose metabolism in patients with AD and different APOE genotypes Neurology 64 2005 102 107 15642911
  11. Dukart J. Bertolino A. When structure affects function--the need for partial volume effect correction in functional and resting state magnetic resonance imaging studies PLoS One 9 2014 e114227 PMC4252146 25460595
  12. Elias-Sonnenschein L.S. Viechtbauer W. Ramakers I.H.G.B. Verhey F.R.J. Visser P.J. Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis J. Neurol. Neurosurg. Psychiatry 82 2011 1149 1156 21493755
  13. Farrer L.A. Cupples L.A. Haines J.L. Hyman B. Kukull W.A. Mayeux R. Myers R.H. Pericak-Vance M.A. Risch N. van Duijn C.M. Effects of age, sex, and ethnicity on the association between Apolipoprotein E genotype and Alzheimer disease: a Meta-analysis JAMA J. Am. Med. Assoc. 1997 9343467
  14. Feussner G. Feussner V. Hoffmann M.M. Lohrmann J. Wieland H. Mrz W. Molecular basis of type III hyperlipoproteinemia in Germany Hum. Mutat. 11 1998 417 423 9603433
  15. Fouquet M. Desgranges B. Landeau B. Duchesnay E. Mezenge F. de la Sayette V. Viader F. Baron J.C. Eustache F. Chetelat G. Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease Brain 132 2009 2058 2067 19477964 PMC2936690
  16. Friedman G. Froom P. Sazbon L. Grinblatt I. Shochina M. Tsenter J. Babaey S. Yehuda A.B. Groswasser Z. Apolipoprotein E- 4 genotype predicts a poor outcome in survivors of traumatic brain injury Neurology. 1999 9932938
  17. Gao R. Zhang G. Chen X. Yang A. Smith G. Wong D.F. Zhou Y. CSF biomarkers and its associations with18F-AV133 cerebral VMAT2 binding in Parkinson's disease-a preliminary report PLoS One 2016 PMC5072678 27764160
  18. Genin E. Hannequin D. Wallon D. Sleegers K. Hiltunen M. Combarros O. Bullido M.J. Engelborghs S. De Deyn P. Berr C. Pasquier F. Dubois B. Tognoni G. Fiévet N. Brouwers N. Bettens K. Arosio B. Coto E. Del Zompo M. Mateo I. Epelbaum J. Frank-Garcia A. Helisalmi S. Porcellini E. Pilotto A. Forti P. Ferri R. Scarpini E. Siciliano G. Solfrizzi V. Sorbi S. Spalletta G. Valdivieso F. Vepsäläinen S. Alvarez V. Bosco P. Mancuso M. Panza F. Nacmias B. Boss P. Hanon O. Piccardi P. Annoni G. Seripa D. Galimberti D. Licastro F. Soininen H. Dartigues J.F. Kamboh M.I. Van Broeckhoven C. Lambert J.C. Amouyel P. Campion D. APOE and Alzheimer disease: a major gene with semi-dominant inheritance Mol. Psychiatry 16 2011 903 907 21556001 PMC3162068
  19. Gottesman R.F. Schneider A.L.C. Zhou Y. Chen X. Green E. Gupta N. Knopman D.S. Mintz A. Rahmim A. Sharrett A.R. Wagenknecht L.E. Wong D.F. Mosley T.H. The ARIC-PET amyloid imaging study: brain amyloid differences by age, race, sex, and APOE Neurology. 2016 PMC4970663 27371485
  20. Grijalva-Eternod C.S. Wells J.C.K. Cortina-Borja M. Salse-Ubach N. Tondeur M.C. Dolan C. Meziani C. Wilkinson C. Spiegel P. Seal A.J. The double burden of obesity and malnutrition in a protracted emergency setting: a cross-sectional study of Western Sahara refugees PLoS Med. 9 2012 PMC3462761 23055833
  21. Hirono N. Hashimoto M. Yasuda M. Ishii K. Sakamoto S. Kazui H. Mori E. The effect of APOE epsilon4 allele on cerebral glucose metabolism in AD is a function of age at onset Neurology 58 2002 743 750 11889238
  22. Hixson J.E. Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI J. Lipid Res. 31 1990 545 548 2341813
  23. Hughes C.P. Berg L. Danziger W.L. A new clinical scale for the staging of dementia Br. J. Psychiatry 140 1982 566 572 7104545
  24. Ingelsson M. Fukumoto H. Newell K.L. Growdon J.H. Hedley-Whyte E.T. Frosch M.P. Albert M.S. Hyman B.T. Irizarry M.C. Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain Neurology. 2004 15037694
  25. Jack C.R. Knopman D.S. Jagust W.J. Petersen R.C. Weiner M.W. Aisen P.S. Shaw L.M. Vemuri P. Wiste H.J. Weigand S.D. Lesnick T.G. Pankratz V.S. Donohue M.C. Trojanowski J.Q. Update on hypothetical model of Alzheimer's disease biomarkers Lancet Neurol. 12 2013 207 216 23332364 PMC3622225
  26. Jonasson L.S. Axelsson J. Riklund K. Boraxbekk C.J. Simulating effects of brain atrophy in longitudinal PET imaging with an anthropomorphic brain phantom Phys. Med. Biol. 62 2017 5213 5227 28561014
  27. Kadotani H. Kadotani T. Young T. Peppard P.E. Finn L. Colrain I.M. Murphy G.M. Mignot E. Association between apolipoprotein E epsilon4 and sleep-disordered breathing in adults JAMA 285 2001 2888 2890 11401610
  28. Kaufer D.I. Cummings J.L. Ketchel P. Smith V. MacMillan A. Shelley T. Lopez O.L. DeKosky S.T. Validation of the NPI-Q, a brief clinical form of the neuropsychiatric inventory J. Neuropsychiatry Clin. Neurosci. 12 2000 233 239 11001602
  29. Knopman D.S. Jack C.R. Wiste H.J. Lundt E.S. Weigand S.D. Vemuri P. Lowe V.J. Kantarci K. Gunter J.L. Senjem M.L. Mielke M.M. Roberts R.O. Boeve B.F. Petersen R.C. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons Neurobiol. Aging 35 2014 2096 2106 24702820 PMC4053507
  30. Lehtovirta M. Kuikka J. Helisalmi S. Hartikainen P. Mannermaa A. Ryynänen M. PSr Riekkinen Soininen H. Longitudinal SPECT study in Alzheimer's disease: relation to apolipoprotein E polymorphism J. Neurol. Neurosurg. Psychiatry 64 1998 742 746 9647302 PMC2170126
  31. Lin K.A. Choudhury K.R. Rathakrishnan B.G. Marks D.M. Petrella J.R. Doraiswamy P.M. Marked gender differences in progression of mild cognitive impairment over 8 years Alzheimer's Dement. Transl. Res. Clin. Interv. 2015 PMC4593067 26451386
  32. Liu C.-C. Liu C.-C. Kanekiyo T. Xu H. Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy Nat. Rev. Neurol. 9 2013 106 118 23296339 PMC3726719
  33. Matsuda H. Cerebral blood flow and metabolic abnormalities in Alzheimer's disease Ann. Nucl. Med. 2001 11448080
  34. Mecca A.P. Barcelos N.M. Wang S. Brück A. Nabulsi N. Planeta-Wilson B. Nadelmann J. Benincasa A.L. Ropchan J. Huang Y. Gelernter J. Van Ness P.H. Carson R.E. van Dyck C.H. Cortical β-amyloid burden, gray matter, and memory in adults at varying APOE ε4 risk for Alzheimer's disease Neurobiol. Aging 61 2018 207 214 29111487 PMC5722236
  35. Misra C. Fan Y. Davatzikos C. Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: Results from ADNI Neuroimage 44 2009 1415 1422 19027862 PMC2648825
  36. Moreno-Grau S. Rodríguez-Gómez O. Sanabria Á. Pérez-Cordón A. Sánchez-Ruiz D. Abdelnour C. Valero S. Hernández I. Rosende-Roca M. Mauleón A. Vargas L. Lafuente A. Gil S. Santos-Santos M.Á. Alegret M. Espinosa A. Ortega G. Guitart M. Gailhajanet A. de Rojas I. Sotolongo-Grau Ó. Ruiz S. Aguilera N. Papasey J. Martín E. Peleja E. Lomeña F. Campos F. Vivas A. Gómez-Chiari M. Tejero M.Á. Giménez J. Serrano-Ríos M. Orellana A. Tárraga L. Ruiz A. Boada M. Exploring APOE genotype effects on Alzheimer's disease risk and amyloid β burden in individuals with subjective cognitive decline: the FundacioACE healthy brain initiative (FACEHBI) study baseline results Alzheimers Dement. 2017 29156223
  37. Mosconi L. Perani D. Sorbi S. Herholz K. Nacmias B. Holthoff V. Salmon E. Baron J.C. De Cristofaro M.T.R. Padovani A. Borroni B. Franceschi M. Bracco L. Pupi A. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET Neurology 63 2004 2332 2340 15623696
  38. Mosconi L. Mistur R. Switalski R. Tsui W.H. Glodzik L. Li Y. Pirraglia E. De Santi S. Reisberg B. Wisniewski T. De Leon M.J. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease Eur. J. Nucl. Med. Mol. Imaging 36 2009 811 822 19142633 PMC2774795
  39. Mosconi L. Berti V. Glodzik L. Pupi A. De Santi S. De Leon M.J. Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging J. Alzheimers Dis. 2010 PMC3038340 20182025
  40. Niethammer M. Feigin A. Eidelberg D. Functional neuroimaging in Parkinson's disease Cold Spring Harb. Perspect. Med. 2012 PMC3331691 22553499
  41. Petersen R.C. Doody R. Kurz A. Mohs R.C. Morris J.C. Rabins P.V. Ritchie K. Rossor M. Thal L. Winblad B. Current concepts in mild cognitive impairment Arch. Neurol. 58 2001 1985 1992 nsa10002 [pii] 11735772
  42. Petersen R.C. Thomas R.G. Grundman M. Bennett D. Doody R. Ferris S. Galasko D. Jin S. Kaye J. Levey A. Pfeiffer E. Sano M. van Dyck C.H. Thal L.J. Alzheimer's Disease Cooperative Study Group Vitamin E and donepezil for the treatment of mild cognitive impairment N. Engl. J. Med. 352 2005 2379 2388 15829527
  43. Pfeffer R.I. Kurosaki T.T. Harrah C.H. Chance J.M. Filos S. Measurement of functional activities in older adults in the community J. Gerontol. 37 1982 323 329 7069156
  44. Pievani M. Bocchetta M. Boccardi M. Cavedo E. Bonetti M. Thompson P.M. Frisoni G.B. Striatal morphology in early-onset and late-onset Alzheimer's disease: a preliminary study Neurobiol. Aging 34 2013 1728 1739 23428181
  45. Prins N.D. Scheltens P. White matter hyperintensities, cognitive impairment and dementia: An update Nat. Rev. Neurol. 2015 25686760
  46. Rajan K.B. Wilson R.S. Weuve J. Barnes L.L. Evans D. a Cognitive impairment 18 years before clinical diagnosis of Alzheimer disease dementia Neurology 85 2015 898 904 26109713 PMC4560057
  47. Reiman E.M. Caselli R.J. Yun L.S. Chen K.W. Bandy D. Minoshima S. Thibodeau S.N. Osborne D. Preclinical evidence of Alzheimers disease in persons homozygous for the ε-4 allele for Apolipoprotein E N. Engl. J. Med. 334 1996 752 758 8592548
  48. Resnick S.M. Sojkova J. Zhou Y. An Y. Ye W. Holt D.P. Dannals R.F. Mathis C.A. Klunk W.E. Ferrucci L. Kraut M.A. Wong D.F. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB Neurology. 2010 PMC2839197 20147655
  49. Roher A.E. Debbins J.P. Malek-Ahmadi M. Chen K. Pipe J.G. Maze S. Belden C. Maarouf C.L. Thiyyagura P. Mo H. Hunter J.M. Kokjohn T.A. Walker D.G. Kruchowsky J.C. Belohlavek M. Sabbagh M.N. Beach T.G. Cerebral blood flow in Alzheimer’s disease Vasc. Health Risk Manag. 42 2012 599 611 PMC3481957 23109807
  50. Rosén C. Hansson O. Blennow K. Zetterberg H. Rosen C. Hansson O. Blennow K. Zetterberg H. Fluid biomarkers in Alzheimer's disease - current concepts Mol. Neurodegener. 8 2013 20 23800368 PMC3691925
  51. Scarabino D. Broggio E. Gambina G. Maida C. Gaudio M.R. Corbo R.M. Apolipoprotein E genotypes and plasma levels in mild cognitive impairment conversion to Alzheimer's disease: a follow-up study Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 171 2016 1131 1138 27604972
  52. Scarmeas N. Anderson K.E. Hilton J. Park A. Habeck C. Flynn J. Tycko B. Stern Y. APOE-dependent PET patterns of brain activation in Alzheimer disease Neurology 63 2004 913 915 63/5/913 [pii]. 15365149 PMC3026570
  53. Schmidt S. Barcellos L.F. DeSombre K. Rimmler J.B. Lincoln R.R. Bucher P. Saunders A.M. Lai E. Martin E.R. Vance J.M. Oksenberg J.R. Hauser S.L. Pericak-Vance M. a Haines J.L. Association of polymorphisms in the apolipoprotein E region with susceptibility to and progression of multiple sclerosis Am. J. Hum. Genet. 70 2002 708 717 11836653 PMC384947
  54. Skup M. Zhu H. Wang Y. Giovanello K.S. Lin J. an Shen D. Shi F. Gao W. Lin W. Fan Y. Zhang H. Sex differences in grey matter atrophy patterns among AD and aMCI patients: Results from ADNI Neuroimage. 2011 PMC3085726 21356315
  55. Small G.W. Ercoli L.M. Silverman D.H. Huang S.C. Komo S. Bookheimer S.Y. Lavretsky H. Miller K. Siddarth P. Rasgon N.L. Mazziotta J.C. Saxena S. Wu H.M. Mega M.S. Cummings J.L. Saunders A.M. Pericak-Vance M.A. Roses A.D. Barrio J.R. Phelps M.E. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease Proc. Natl. Acad. Sci. U. S. A. 97 2000 6037 6042 10811879 PMC18554
  56. Sundermann E.E. Biegon A. Rubin L.H. Lipton R.B. Landau S. Maki P.M. Does the female advantage in verbal memory contribute to underestimating Alzheimer's disease pathology in women versus men? J. Alzheimers Dis. 2017 PMC7644197 28106548
  57. Tang X. Hollandb D. Dale A.M. Miller M.I. APOE affects the volume and shape of the amygdala and the Hippocampus in mild cognitive impairment and Alzheimer's disease: age matters J. Alzheimers Dis. 47 2015 645 660 26401700 PMC5479937
  58. Thambisetty M. Beason-Held L. An Y. Kraut M.A. Resnick S.M. APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging Arch. Neurol. 67 2010 93 98 20065135 PMC2856443
  59. Thambisetty M. Tripaldi R. Riddoch-Contreras J. Hye A. An Y. Campbell J. Sojkova J. Kinsey A. Lynham S. Zhou Y. Ferrucci L. Wong D.F. Lovestone S. Resnick S.M. Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals J. Alzheimers Dis. 2010 PMC3125970 20930274
  60. Tohka J. Reilhac A. Deconvolution-based partial volume correction in Raclopride-PET and Monte Carlo comparison to MR-based method Neuroimage 39 2008 1570 1584 18077187
  61. Tosto G. Zimmerman M.E. Hamilton J.L. Carmichael O.T. Brickman A.M. The effect of white matter hyperintensities on neurodegeneration in mild cognitive impairment Alzheimers Dement. 2015 PMC4677059 26079417
  62. Winblad B. Palmer K. Kivipelto M. Jelic V. Fratiglioni L. Wahlund L.O. Nordberg A. Bäckman L. Albert M. Almkvist O. Arai H. Basun H. Blennow K. de Leon M. DeCarli C. Erkinjuntti T. Giacobini E. Graff C. Hardy J. Jack C. Jorm A. Ritchie K. van Duijn C. Visser P. Petersen R.C. Mild cognitive impairment--beyond controversies, towards a consensus: report of the international working group on mild cognitive impairment J. Intern. Med. 256 2004 240 246 15324367
  63. Wolk D. a Dickerson B.C. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease Proc. Natl. Acad. Sci. U. S. A. 107 2010 10256 10261 20479234 PMC2890481
  64. Zhang Z. Mu J. Li J. Li W. Song J. Aberrant Apolipoprotein E expression and cognitive dysfunction in patients with Poststroke depression Genet. Test. Mol. Biomarkers 17 2013 47 51 23171142 PMC3525887
  65. Zhou Y. Resnick S.M. Ye W. Fan H. Holt D.P. Klunk W.E. Mathis C.A. Dannals R. Wong D.F. Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease Neuroimage. 2007 PMC2001263 17449282

Cited by

Sorted by citations

Authors
Paranjpe, M. D., Chen, X., Liu, M., Paranjpe, I., Leal, J. P., Wang, R., Pomper, M. G., Wong, D. F., Benzinger, T. L. S., & Zhou, Y.
Affiliations
  • Johns Hopkins University (US)
  • Peking University First Hospital (CN)
  • Icahn School of Medicine at Mount Sinai (US)
  • Washington University in St. Louis (US)
Corresponding author
Zhou, Yun
ORCID
Venue
NeuroImage: Clinical
Publisher
Elsevier BV
Published
2019
Volume
22
Pages
101795
ISSN
2213-1582 (ISSN-L)
DOI
10.1016/j.nicl.2019.101795
PMC
PMC6449776
OpenAlex
W2927152915
Cited by
51
References
7
Citations by year
2026: 5 · 2025: 10 · 2024: 7 · 2023: 5 · 2022: 5 · 2021: 11 · 2020: 5 · 2019: 3
FWCI
4.68
Type
journal article
Language
en
Open access
Licence
Locations
  • NeuroImage Clinical (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institutes of Health
  • National Institute on Aging
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
APOE ε4, mild cognitive impairment, brain glucose metabolism, partial volume correction, Alzheimer's disease risk, amygdala, medial temporal lobe
MeSH terms
Aged, Aged, 80 and over, Apolipoproteins E, Brain, Female, Glucose, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Middle Aged, Fluorodeoxyglucose F18, Positron-Emission Tomography, Apolipoprotein E4, Neuroimaging, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review